Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial

ABSTRACT: Male breast cancer (BC) is rare, globally constituting only 0.5–1% of all patients with BC. In Italy, more than 2000 new male BC cases were registered between 2000 and 2014. The survival rate was lower in males than in females. Delayed diagnosis may be the reason for poorer outcome observe...

Descripción completa

Detalles Bibliográficos
Autores principales: Caputo, Roberta, Fabi, Alessandra, Romagnoli, Emanuela, Baldini, Editta, Grasso, Donatella, Fenderico, Nicola, Michelotti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576937/
https://www.ncbi.nlm.nih.gov/pubmed/36267663
http://dx.doi.org/10.2147/BCTT.S376902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576937/
https://www.ncbi.nlm.nih.gov/pubmed/36267663
http://dx.doi.org/10.2147/BCTT.S376902

Ejemplares similares